Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.

Breast Cancer Res · 2023 · PMC10648326 · PMID 37968696

Europe PMC DOI

hedged sentence

0.3500

closest p · 7.0× alpha

0.3500

boldest claim

The sentences

failed to reach statistical significancep = 0.35not close (p > 0.1)

Of note, ERBB2 mutations were numerically higher in HER2+ MBC (9 out of 68) compared to HER2+ PBC (2 out of 73, uncorrected Fisher exact p = 0.027), but this failed to reach statistical significance after correcting for multiple testing ( p = 0.35).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.